Aerpio pharmaceuticals, inc. (ARPO)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Operating activities:
Net and comprehensive loss

-18,696

-23,270

-27,342

-11,157

-11,463

-10,396

-8,113

-24,300

-23,830

-21,400

-18,683

-18,919

-21,972

-16,983

-30,516

-25,637

-17,070

-17,070

-31

-31

-30

-30

-28

-28

-28

-28

-28

-28

-28

-27

-26

-26

-27

-27

0

0

0

Adjustments to reconcile net and comprehensive loss to net cash used in operating activities:
Depreciation

78

76

65

56

47

46

47

47

50

51

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

791

1,085

2,540

2,700

2,973

3,431

3,019

2,339

1,573

649

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Consulting expenses related to warrants

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

-

-

-

-

-

-

-

-

-

75

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense related to convertible note conversion

-

-

-

-

-

-

-

-

-

204

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid research and development contracts

-111

-443

201

-60

-108

441

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

31

119

-18

50

138

293

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and current other assets

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and other current liabilities

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

2

7

5

1

-3

-8

-1

-1

1

0

0

0

0

0

0

Increase in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-8

-6

9

2

10

7

-5

-1

0

0

2

-1

-2

-2

0

0

0

0

0

Increase in accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

7

7

6

6

6

6

5

5

5

5

4

4

4

3

3

0

0

0

Increase in accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-0

0

-3

3

0

0

5

0

1

1

0

0

0

0

0

-

-

-

-

Increase (decrease) in accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-18,714

-23,852

-25,172

-26,631

-8,372

-5,808

0

0

0

-

-

-

-

-

-

-

-17,888

-17,884

-31

-29

-17

-16

-7

-13

-21

-23

-20

-15

-20

-24

-25

-24

-26

-22

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities:
Purchase of furniture and equipment

-

236

245

262

142

37

31

10

15

8

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-236

-245

-262

-142

-37

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities:
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

76

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuances of convertible notes

-

-

-

-

-

-

-

-

-

297

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on notes payable, stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

Payments on notes payable, stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Proceeds from sale of common stock

-

-

-

-

-

-

-

-

-

40,247

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

Cash paid in connection with the sale of common stock

-

-

-

-

-

-

-

-

-

3,084

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from notes payable, stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

35

35

15

15

0

25

25

0

0

0

-

-

-

25

0

0

0

0

Net cash provided by financing activities

-

-

-

-

-

48,195

0

0

0

-

-

-

-

-

-

-

-17

3

20

35

35

15

15

0

25

25

25

25

0

25

25

25

25

0

0

0

0

Net decrease in cash and cash equivalents

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

39,935

-21,375

18,654

23,520

27,245

30,000

-3,534

-21,759

-21,469

-17,946

-17,922

-11

5

17

-1

7

-13

3

1

4

9

-20

0

-0

0

-1

-22

0

0

0

Conversion of redeemable convertible preferred stock into common stock

-

-

-

-

-

-

-

-

-

74,701

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of convertible notes and accrued interest into common stock

-

-

-

-

-

-

-

-

-

13,447

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

943

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-